Published in PLoS One on July 23, 2012
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Mod Pathol (2016) 0.80
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol (2016) 0.79
An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. BMC Cancer (2017) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood (2006) 5.43
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood (2005) 3.90
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica (2007) 2.19
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia (2006) 1.51
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood (2009) 1.47
Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol (2006) 1.28
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia (2009) 1.28
GATA1-related leukaemias. Nat Rev Cancer (2008) 1.20
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood (1992) 1.12
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol (2008) 1.12
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol (2010) 1.07
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica (2011) 1.04
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood (2006) 1.01
Acute erythroleukemia: diagnosis and management. Expert Rev Hematol (2010) 0.98
FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol (2011) 0.98
Acute erythroid leukemia. Arch Pathol Lab Med (2010) 0.89
Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. Eur J Haematol (2011) 0.81
Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol (2008) 0.81
Genetic deletions in AML and MDS. Best Pract Res Clin Haematol (2010) 0.79
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Dynamic visualization of thrombopoiesis within bone marrow. Science (2007) 4.35
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Leukemia cutis. Am J Clin Pathol (2008) 3.38
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol (2007) 3.13
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol (2010) 2.82
Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol (2012) 2.76
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol (2002) 2.48
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res (2005) 2.46
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol (2012) 2.21
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer (2003) 2.21
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood (2009) 2.15
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer (2008) 2.07
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol (2014) 2.04
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One (2009) 1.97
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene (2004) 1.95
Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch (2014) 1.93
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer (2007) 1.88
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol (2012) 1.87
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood (2008) 1.86
Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol (2013) 1.84
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res (2006) 1.84
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med (2003) 1.81
8p11 myeloproliferative syndrome: a review. Hum Pathol (2010) 1.81
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2011) 1.75
Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet (2011) 1.75
Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol (2008) 1.75
Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J (2009) 1.72
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res (2011) 1.72
Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res (2009) 1.71
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol (2006) 1.64
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood (2009) 1.62
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood (2011) 1.61
Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma (2010) 1.61
Nutrient intake and anemia risk in the women's health initiative observational study. J Am Diet Assoc (2011) 1.60
Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study. Am J Clin Nutr (2014) 1.60
Imputation of exome sequence variants into population- based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genet (2012) 1.60
Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol (2006) 1.59
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res (2013) 1.56
Clinical risk factors for fractures in multi-ethnic women: the Women's Health Initiative. J Bone Miner Res (2007) 1.56
Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause (2011) 1.56
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma (2006) 1.55
Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med (2003) 1.52
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood (2008) 1.52
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol (2009) 1.51
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma (2013) 1.49
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
EBV-positive diffuse large B-cell lymphoma of the elderly. Blood (2013) 1.49
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol (2008) 1.49
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol (2011) 1.49
Performance evaluation of a multiplex assay for future use in biomarker discovery efforts to predict body composition. Clin Chem Lab Med (2011) 1.48
Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem (2011) 1.48
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood (2009) 1.47
Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn (2010) 1.47
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47